Ann: Change in substantial holding, page-45

Platinum would have been hoping to sell it's 10% holding to big Pharma at $1 for $110 million, rather than dumping the whole lot on market at 7.5 cents or $825,000. Platinum will have this dud off it's books totally, embarrassing doing marketing with a dud like PER in the portfolio...

57% of shares on issue have traded at 7.5 cents , at or below cash backing, suggests there were a lot of hedge funds etc following Platinum . With Platinum gone , PER has lost it's only partner , now totally retail , can't rule out PER winding the company up and returning what cash there is, 100% fail across all pharmacological activity means a hard road ahead . PER has a valuable team, but is that an asset or a liability in this scenario